Literature DB >> 11333271

Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121).

G B Whitaker1, B J Limberg, J S Rosenbaum.   

Abstract

The two most abundant secreted isoforms of vascular endothelial growth factor A (VEGF(165) and VEGF(121)) are formed as a result of differential splicing of the VEGF-A gene. VEGF(165) and VEGF(121) share similar affinities at the isolated VEGF receptor (VEGFR)-2 but have been previously demonstrated to have differential ability to activate VEGFR-2-mediated effects on endothelial cells. Herein we investigate whether the recently described VEGF(165) isoform-specific receptor neuropilin-1 (Npn-1) is responsible for the difference in potency observed for these ligands. We demonstrate that although VEGFR-2 and Npn-1 form a complex, this complex does not result in an increase in VEGF(165) binding affinity. Therefore, the differential activity of VEGF(165) and VEGF(121) cannot be explained by a differential binding affinity for the complex. Using an antagonist that competes for VEGF(165) binding at the VEGFR-2.Npn-1 complex, we observe specific antagonism of VEGF(165)-meditated phosphorylation of VEGFR-2 without affecting the VEGF(121) response. These data indicate that the formation of the complex is responsible for the increased potency of VEGF(165) versus VEGF(121). Taken together, these data suggest a receptor-clustering role for Npn-1, as opposed to Npn-1 behaving as an affinity-converting subunit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333271     DOI: 10.1074/jbc.M102315200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Dynamic modules and heterogeneity of function: a lesson from tyrosine kinase receptors in endothelial cells.

Authors:  F Bussolino; G Serini; S Mitola; G Bazzoni; E Dejana
Journal:  EMBO Rep       Date:  2001-09       Impact factor: 8.807

2.  VEGFA family isoforms regulate spermatogonial stem cell homeostasis in vivo.

Authors:  Kyle C Caires; Jeanene M de Avila; Andrea S Cupp; Derek J McLean
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

Review 3.  Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer.

Authors:  Atsuko Sakurai; Colleen L Doçi; Colleen Doci; J Silvio Gutkind
Journal:  Cell Res       Date:  2011-12-13       Impact factor: 25.617

4.  Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair.

Authors:  Detlev Roth; Michael Piekarek; Mats Paulsson; Hildegard Christ; Wilhelm Bloch; Thomas Krieg; Jeffrey M Davidson; Sabine A Eming
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 5.  Neuropilin, you gotta let me know: should I stay or should I go?

Authors:  Quenten Schwarz; Christiana Ruhrberg
Journal:  Cell Adh Migr       Date:  2010-01-29       Impact factor: 3.405

Review 6.  Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion.

Authors:  Martine Perrot-Applanat; Melanie Di Benedetto
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

7.  Neuropilin ligands in vascular and neuronal patterning.

Authors:  Alessandro Fantin; Charlotte H Maden; Christiana Ruhrberg
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

Review 8.  The role of semaphorins and their receptors in vascular development and cancer.

Authors:  Chenghua Gu; Enrico Giraudo
Journal:  Exp Cell Res       Date:  2013-02-17       Impact factor: 3.905

9.  Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity.

Authors:  H Jia; L Cheng; M Tickner; A Bagherzadeh; D Selwood; I Zachary
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.